IN8bio, Inc. (INAB)
NASDAQ$0.2285
Market Cap
$18.57M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
640 of 924
Rank in Industry
366 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
INAB Insider Trading Activity
INAB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. …
Insider Activity of IN8bio, Inc.
Over the last 12 months, insiders at IN8bio, Inc. have bought $0 and sold $0 worth of IN8bio, Inc. stock.
On average, over the past 5 years, insiders at IN8bio, Inc. have bought $1.44M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $2,375 was made by Graff Jeremy R. (director) on 2023‑09‑13.
List of Insider Buy and Sell Transactions, IN8bio, Inc.
| 2023-09-13 | Graff Jeremy R. | director | 2,500 0.0077% | $0.95 | $2,375 | +8.98% | ||
| 2023-08-25 | McCall Patrick | Chief Financial Officer | 1,000 0.0032% | $1.03 | $1,030 | +0.49% | ||
| 2023-08-24 | Ho William Tai-Wei | President and CEO | 23,800 0.0719% | $1.05 | $24,990 | +0.98% | ||
| 2022-12-12 | Kreis Leslie W. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-12-12 | Fletcher Aaron G.L. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-09-28 | Kreis Leslie W. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-09-28 | Fletcher Aaron G.L. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-08-26 | Cavu Advisors, LLC | 31,805 0.1513% | $2.02 | $64,232 | -5.36% | |||
| 2022-08-17 | Cavu Advisors, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-17 | BIOS Advisors GP, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-16 | Transcend Partners Opportunity Fund LLC | 789,473 3.713% | $1.90 | $1.5M | +0.53% | |||
| 2022-08-16 | Ho William Tai-Wei | President, CEO and CFO | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | ||
| 2022-08-16 | Cavu Advisors, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | BIOS Advisors GP, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | Brandt Peter C. | 105,263 0.4951% | $1.90 | $200,000 | +0.53% | |||
| 2022-08-16 | Lamb Lawrence | EVP and CSO | 526 0.0025% | $1.90 | $999 | +0.53% | ||
| 2022-08-16 | Roemer Alan S. | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | |||
| 2022-08-16 | Greenwood Luba | 526 0.0025% | $1.90 | $999 | +0.53% | |||
| 2022-08-16 | Rochlin Kate | Chief Operating Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% | ||
| 2022-08-16 | McCall Patrick | Chief Financial Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% |
Total: 22
Insider Historical Profitability
<0.0001%
| Transcend Partners Opportunity Fund LLC | 4111958 5.0603% | $939,582.40 | 1 | 0 | ||
| Fletcher Aaron G.L. | director | 3727597 4.5873% | $851,755.91 | 2 | 0 | |
| Kreis Leslie W. | director | 3727597 4.5873% | $851,755.91 | 2 | 0 | |
| Cavu Advisors, LLC | 3651528 4.4937% | $834,374.15 | 3 | 0 | ||
| BIOS Advisors GP, LLC | 3612569 4.4458% | $825,472.02 | 2 | 0 |
Historical Insider Profitability vs. Competitors
$992,222,850 | 90 | -12.52% | $19.41M | |
$6,204,522 | 45 | 1.91% | $19.55M | |
$550,024 | 37 | -2.68% | $20.67M | |
$85,897,100 | 36 | 2.47% | $17.48M | |
$4,368,362 | 28 | -22.35% | $17.38M |
INAB Institutional Investors: Active Positions
| Increased Positions | 16 | +69.57% | 24M | +318.79% |
| Decreased Positions | 9 | -39.13% | 2M | -20.89% |
| New Positions | 5 | New | 14M | New |
| Sold Out Positions | 4 | Sold Out | 904,530 | Sold Out |
| Total Postitions | 30 | +30.43% | 30M | +297.89% |
INAB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bios Capital Management, Lp | $1,935.00 | 10.62% | 8.6M | +9M | New | 2024-12-31 |
| Aigh Capital Management Llc | $1,393.00 | 7.64% | 6.19M | +5M | +269.74% | 2024-12-31 |
| Franklin Resources Inc | $1,282.00 | 7.03% | 5.7M | +6M | New | 2024-12-31 |
| Alyeska Investment Group, L.P. | $1,139.00 | 6.25% | 5.06M | +5M | +1,064.49% | 2024-12-31 |
| Vanguard Group Inc | $320.00 | 1.76% | 1.42M | 0 | 0% | 2024-12-31 |
| Sigma Planning Corp | $234.00 | 1.29% | 1.04M | +190,100 | +22.33% | 2024-12-31 |
| 683 Capital Management, Llc | $169.00 | 0.93% | 750,000 | -600,304 | -44.46% | 2024-12-31 |
| Geode Capital Management, Llc | $116.00 | 0.64% | 515,193 | +185,919 | +56.46% | 2024-12-31 |
| Stonegate Investment Group, Llc | $41.00 | 0.22% | 180,000 | 0 | 0% | 2024-12-31 |
| Jane Street Group, Llc | $26.00 | 0.14% | 115,919 | +86,696 | +296.67% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.